|
1
|
Rinella ME: Nonalcoholic fatty liver
disease: A systematic review. JAMA. 313:2263–2273. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Diehl AM and Day C: Cause, pathogenesis,
and treatment of nonalcoholic steatohepatitis. N Engl J Med.
377:2063–2072. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
National Workshop on Fatty Liver and
Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese
Medical Association; Fatty Liver Expert Committee, Chinese Medical
Doctor Association. Guidelines of prevention and treatment for
nonalcoholic fatty liver disease: A 2018 update. Zhonghua Gan Zang
Bing Za Zhi. 26:195–203. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
4
|
Charlton MR, Burns JM, Pedersen RA, Watt
KD, Heimbach JK and Dierkhising RA: Frequency and outcomes of liver
transplantation for nonalcoholic steatohepatitis in the United
States. Gastroenterology. 141:1249–1253. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lonardo A, Nascimbeni F, Mantovani A and
Targher G: Hypertension, diabetes, atherosclerosis and NASH: Cause
or consequence? J Hepatol. 68:335–352. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ratziu V, Goodman Z and Sanyal A: Current
efforts and trends in the treatment of NASH. J Hepatol. 62 (Suppl
1):S65–S75. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lefebvre P, Cariou B, Lien F, Kuipers F
and Staels B: Role of bile acids and bile acid receptors in
metabolic regulation. Physiol Rev. 89:147–191. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Verbeke L, Mannaerts I, Schierwagen R,
Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M,
Mazzone M, et al: FXR agonist obeticholic acid reduces hepatic
inflammation and fibrosis in a rat model of toxic cirrhosis. Sci
Rep. 6(33453)2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang DG, Zhang C, Wang JX, Wang BW, Wang
H, Zhang ZH, Chen YH, Lu Y, Tao L, Wang JQ, et al: Obeticholic acid
protects against carbon tetrachloride-induced acute liver injury
and inflammation. Toxicol Appl Pharmacol. 314:39–47.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mudaliar S, Henry RR, Sanyal AJ, Morrow L,
Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe
E, et al: Efficacy and safety of the farnesoid X receptor agonist
obeticholic acid in patients with type 2 diabetes and nonalcoholic
fatty liver disease. Gastroenterology. 145:574–582.e1.
2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Neuschwander-Tetri BA, Loomba R, Sanyal
AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy
S, Diehl AM, Hameed B, et al: Farnesoid X nuclear receptor ligand
obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis
(FLINT): A multicentre, randomised, placebo-controlled trial.
Lancet. 385:956–965. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ratziu V, Sanyal AJ, Loomba R, Rinella M,
Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L,
Shringarpure R, et al: REGENERATE: Design of a pivotal, randomised,
phase 3 study evaluating the safety and efficacy of obeticholic
acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Contemp Clin Trials. 84(105803)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Briand F, Brousseau E, Quinsat M, Burcelin
R and Sulpice T: Obeticholic acid raises LDL-cholesterol and
reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster
model. Eur J Pharmacol. 818:449–456. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Papazyan R, Liu X, Liu J, Dong B, Plummer
EM, Lewis RD II, Roth JD and Young MA: FXR activation by
obeticholic acid or nonsteroidal agonists induces a human-like
lipoprotein cholesterol change in mice with humanized chimeric
liver. J Lipid Res. 59:982–993. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
McTaggart F and Jones P: Effects of
statins on high-density lipoproteins: A potential contribution to
cardiovascular benefit. Cardiovasc Drugs Ther. 22:321–338.
2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Maron DJ, Fazio S and Linton MF: Current
perspectives on statins. Circulation. 101:207–213. 2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ,
Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional
fibrosis and steatohepatitis in mice. Scand J Gastroenterol.
44:358–365. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kleiner DE, Brunt EM, Van Natta M, Behling
C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS,
Unalp-Arida A, et al: Design and validation of a histological
scoring system for nonalcoholic fatty liver disease. Hepatology.
41:1313–1321. 2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang HJ, Pan LL, Ma ZM, Chen Z, Huang ZF,
Sun Q, Lu Y, Han CK, Lin MZ, Li XJ, et al: Long-term effect of
exercise on improving fatty liver and cardiovascular risk factors
in obese adults: A 1-year follow-up study. Diabetes Obes Metab.
19:284–289. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hoeke MO, Heegsma J, Hoekstra M, Moshage H
and Faber KN: Human FXR regulates SHP expression through direct
binding to an LRH-1 binding site, independent of an IR-1 and LRH-1.
PLoS One. 9(e88011)2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chambers KF, Day PE, Aboufarrag HT and
Kroon PA: Polyphenol effects on cholesterol metabolism via bile
acid biosynthesis, CYP7A1: A review. Nutrients.
11(2588)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Li D, Zhao D, Du J, Dong S, Aldhamin Z,
Yuan X, Li W, Du H, Zhao W, Cui L, et al: Heme oxygenase-1
alleviated non-alcoholic fatty liver disease via suppressing
ROS-dependent endoplasmic reticulum stress. Life Sci.
253(117678)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pockros PJ, Fuchs M, Freilich B, Schiff E,
Kohli A, Lawitz EJ, Hellstern PA, Owens-Grillo J, Van Biene C,
Shringarpure R, et al: CONTROL: A randomized phase 2 study of
obeticholic acid and atorvastatin on lipoproteins in nonalcoholic
steatohepatitis patients. Liver Int. 39:2082–2093. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hu YB, Liu XY and Zhan W: Farnesoid X
receptor agonist INT-767 attenuates liver steatosis and
inflammation in rat model of nonalcoholic steatohepatitis. Drug Des
Devel Ther. 12:2213–2221. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hameed B, Terrault NA, Gill RM, Loomba R,
Chalasani N, Hoofnagle JH and Van Natta ML: NASH CRN. Clinical and
metabolic effects associated with weight changes and obeticholic
acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther.
47:645–656. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tolbol KS, Kristiansen MN, Hansen HH,
Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N and Feigh M:
Metabolic and hepatic effects of liraglutide, obeticholic acid and
elafibranor in diet-induced obese mouse models of biopsy-confirmed
nonalcoholic steatohepatitis. World J Gastroenterol. 24:179–194.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kim SG, Kim BK, Kim K and Fang S: Bile
acid nuclear receptor Farnesoid X receptor: Therapeutic target for
nonalcoholic fatty liver disease. Endocrinol Metab (Seoul).
31:500–504. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Carino A, Biagioli M, Marchianò S,
Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E
and Fiorucci S: Ursodeoxycholic acid is a GPBAR1 agonist and resets
liver/intestinal FXR signaling in a model of diet-induced dysbiosis
and NASH. Biochim Biophys Acta Mol Cell Biol Lipids.
1864:1422–1437. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Byun HW, Hong EM, Park SH, Koh DH, Choi
MH, Jang HJ, Kae SH and Lee J: Pravastatin activates the expression
of farnesoid X receptor and liver X receptor alpha in Hep3B cells.
Hepatobiliary Pancreat Dis Int. 13:65–73. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Fu ZD, Cui JY and Klaassen CD:
Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by
suppressing FXR signaling in both liver and intestine in mice. J
Lipid Res. 55:2576–2586. 2014.PubMed/NCBI View Article : Google Scholar
|
